140 related articles for article (PubMed ID: 34979067)
1. Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis Patients, Single-Center, Prospective, Open-Label, Single-Arm Clinical Trial, Long-Term Follow-up.
Nabavi SM; Karimi SH; Arab L; Sanjari L; Mardpour S; Azimian V; Jarughi N; Ghaheri A; Hosseini SE; Aghdami N; Vosough M
Cell J; 2021 Dec; 23(7):772-778. PubMed ID: 34979067
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of bone marrow derived-mesenchymal stem cells transplantation in patients with amyotrophic lateral sclerosis.
Tavakol-Afshari J; Boroumand AR; Farkhad NK; Adhami Moghadam A; Sahab-Negah S; Gorji A
Regen Ther; 2021 Dec; 18():268-274. PubMed ID: 34466632
[TBL] [Abstract][Full Text] [Related]
4. Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial.
Nabavi SM; Arab L; Jarooghi N; Bolurieh T; Abbasi F; Mardpour S; Azimyian V; Moeininia F; Maroufizadeh S; Sanjari L; Hosseini SE; Aghdami N
Cell J; 2019 Jan; 20(4):592-598. PubMed ID: 30124008
[TBL] [Abstract][Full Text] [Related]
5. The Efficacy and Safety of Intrathecal Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis: A Pilot Study.
Shamsaei G; Houshmand F; Ahmadzadeh Deylami A; Valizadeh A; Rafie S; Moradi M
Adv Pharm Bull; 2023 Mar; 13(2):361-367. PubMed ID: 37342380
[No Abstract] [Full Text] [Related]
6. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
[TBL] [Abstract][Full Text] [Related]
7. Transplantation of Mesenchymal Stromal Cells in Patients With Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial.
Syková E; Rychmach P; Drahorádová I; Konrádová Š; Růžičková K; Voříšek I; Forostyak S; Homola A; Bojar M
Cell Transplant; 2017 Apr; 26(4):647-658. PubMed ID: 27938483
[TBL] [Abstract][Full Text] [Related]
8. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
Petrou P; Kassis I; Yaghmour NE; Ginzberg A; Karussis D
Front Biosci (Landmark Ed); 2021 Oct; 26(10):693-706. PubMed ID: 34719198
[No Abstract] [Full Text] [Related]
9. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Karussis D; Karageorgiou C; Vaknin-Dembinsky A; Gowda-Kurkalli B; Gomori JM; Kassis I; Bulte JW; Petrou P; Ben-Hur T; Abramsky O; Slavin S
Arch Neurol; 2010 Oct; 67(10):1187-94. PubMed ID: 20937945
[TBL] [Abstract][Full Text] [Related]
11. Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study.
Kim HY; Kim H; Oh KW; Oh SI; Koh SH; Baik W; Noh MY; Kim KS; Kim SH
Stem Cells; 2014 Oct; 32(10):2724-31. PubMed ID: 24966156
[TBL] [Abstract][Full Text] [Related]
12. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study.
Prabhakar S; Marwaha N; Lal V; Sharma RR; Rajan R; Khandelwal N
Neurol India; 2012; 60(5):465-9. PubMed ID: 23135021
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
14. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS.
Staff NP; Madigan NN; Morris J; Jentoft M; Sorenson EJ; Butler G; Gastineau D; Dietz A; Windebank AJ
Neurology; 2016 Nov; 87(21):2230-2234. PubMed ID: 27784774
[TBL] [Abstract][Full Text] [Related]
15. Repeat Administration of Bone Marrow-Derived Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis.
Siwek T; Jezierska-Woźniak K; Maksymowicz S; Barczewska M; Sowa M; Badowska W; Maksymowicz W
Med Sci Monit; 2020 Dec; 26():e927484. PubMed ID: 33301428
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results.
Gotkine M; Caraco Y; Lerner Y; Blotnick S; Wanounou M; Slutsky SG; Chebath J; Kuperstein G; Estrin E; Ben-Hur T; Hasson A; Molakandov K; Sonnenfeld T; Stark Y; Revel A; Revel M; Izrael M
J Transl Med; 2023 Feb; 21(1):122. PubMed ID: 36788520
[TBL] [Abstract][Full Text] [Related]
17. Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study.
Farge D; Loisel S; Resche-Rigon M; Lansiaux P; Colmegna I; Langlais D; Charles C; Pugnet G; Maria ATJ; Chatelus E; Martin T; Hachulla E; Kheav VD; Lambert NC; Wang H; Michonneau D; Martinaud C; Sensebé L; Cras A; Tarte K
Lancet Rheumatol; 2022 Feb; 4(2):e91-e104. PubMed ID: 38288741
[TBL] [Abstract][Full Text] [Related]
18. Six-Minute Walk Test as a Measure of Walking Capacity in Ambulatory Individuals With Amyotrophic Lateral Sclerosis.
Sanjak M; Langford V; Holsten S; Rozario N; Patterson CGM; Bravver E; Bockenek WL; Brooks BR
Arch Phys Med Rehabil; 2017 Nov; 98(11):2301-2307. PubMed ID: 28465220
[TBL] [Abstract][Full Text] [Related]
19. Effect of mesenchymal stromal cell transplantation on long-term survival in amyotrophic lateral sclerosis.
De Marchi F; Mareschi K; Ferrero I; Cantello R; Fagioli F; Mazzini L
Cytotherapy; 2023 Aug; 25(8):798-802. PubMed ID: 36931995
[TBL] [Abstract][Full Text] [Related]
20. Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis.
Li X; Koeberl DD; Lutz MW; Bedlack R
J Clin Neuromuscul Dis; 2023 Jun; 24(4):214-221. PubMed ID: 37219865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
